EN DE
Watch Santhera Pharmaceuticals Holding AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Santhera Pharmaceuticals Holding AG (SANN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Santhera Pharmaceuticals Holding AG stock CHF 15.04, price CHF 14.94, upside +0.7%, quality 19 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0027148649

SP Santhera Pharmaceuticals Holding AG logo Thin data Nov 10, 2026

Santhera Pharmaceuticals Holding AG

SANN · SW
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Generates free cash flow over the last twelve months
Revenue last quarter +101% vs. a year ago.
Fair value CHF 15.04 · Fairly valued
Mixed Growth (revenue 5y +38.8 %/yr in CHF)
Negative equity (buybacks among others)
Mixed vs. peers (3/7)
Quality 19/100
Loss-making · -31.5% net margin (TTM)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Santhera Pharmaceuticals Holding AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 24.70 CHF 5.00 Fair Value CHF 15.04 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range CHF 5.00 – CHF 24.70 · fair‑value band CHF 11.28 – CHF 18.80 · the CHF 14.94 price screens below the CHF 15.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Santhera Pharmaceuticals Holding in your weekly email

Every Wednesday you see whether Santhera Pharmaceuticals Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

Show moreShow less

The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Stock analysis

Santhera Pharmaceuticals Holding AG (SANN) currently trades at CHF 14.94, while our estimate is CHF 15.04, so the stock looks roughly fairly valued today (gap 0.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: CHF 11.28 (bear) to CHF 18.80 (bull), the price of CHF 14.94 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Santhera Pharmaceuticals Holding AG reported revenue of CHF 77.2M in FY2025 versus −CHF 1.6M in FY2021. Reported net income was −CHF 49.2M in FY2025.

Key figures

Market cap CHF 239M Micro · P/S ratio 2.31 · EPS (TTM) CHF −2.24 · Net margin −31.5% · Return on equity −620% · Return on assets (EBIT) −25.7% (5-year average) · Operating margin −13.6% · Revenue (TTM) CHF 102M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 1%, SANN screens cheaper than that median.

Fair Value

Bear CHF 11.28 Fair Value CHF 15.04 Bull CHF 18.80
Price CHF 14.94 · Upside +0.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 19/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 17
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 61
How calm the share price moves, does not count
Price momentum 48
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+97.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+117.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.8%
Start year 2020 (pandemic). Over 10 years: +33.4% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−353.7% (2020) → −49.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SANN, get fair value alerts →

Compare Santhera Pharmaceuticals Holding AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 19 · Bottom 25%
Fair Value upside +0.7% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −33.3% · Below median
Net margin (12 months) −31.5% · Below median
Operating margin (12 months) −13.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 101.3% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 2.35× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)34 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SANN
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SANN
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SANN
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SANN
argenx SE ARGX $971.55 $908.40 −7% vs SANN
CSL Limited CSL A$201.68 A$181.40 −10% vs SANN
Moderna, Inc MRNA $250.83 $158.70 −37% vs SANN
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SANN
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SANN
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SANN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Santhera Pharmaceuticals Holding AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Santhera Pharmaceuticals Holding AG Fair Value". https://www.fairvalue-calculator.com/stock/SANN

Frequently asked questions

Is Santhera Pharmaceuticals Holding AG (SANN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is CHF 15.04 versus a price of CHF 14.94, about +1% upside (fairly valued).
What is the fair value of SANN?
Our estimate for Santhera Pharmaceuticals Holding AG is CHF 15.04 (as of Nov 10, 2026), built from audited fundamentals. The current price: CHF 14.94.
What is the quality score of SANN?
Santhera Pharmaceuticals Holding AG has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Santhera Pharmaceuticals Holding AG (SANN)?
Our calculated price target is the estimate of CHF 15.04 (as of Nov 10, 2026). Cautious scenario CHF 11.28, optimistic scenario CHF 18.80. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Santhera Pharmaceuticals Holding AG stock forecast for 2026?
Our estimate puts fair value at CHF 15.04, about +1% upside versus a price of CHF 14.94 (fairly valued). Cautious scenario CHF 11.28, optimistic scenario CHF 18.80. The calculation is refreshed regularly with new filings.
What is the revenue of Santhera Pharmaceuticals Holding AG (SANN)?
Santhera Pharmaceuticals Holding AG reported trailing-twelve-month revenue of about CHF 102M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Santhera Pharmaceuticals Holding AG (SANN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Santhera Pharmaceuticals Holding AG it is CHF 15.04 per share (as of Nov 10, 2026), against a price of CHF 14.94.
Is Santhera Pharmaceuticals Holding AG stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SANN trades below its calculated fair value: price CHF 14.94, fair value CHF 15.04, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SANN?
No. The price is what the market pays today (CHF 14.94); the fair value is what the company's own numbers justify (CHF 15.04). For Santhera Pharmaceuticals Holding AG the two are CHF 0.1000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Santhera Pharmaceuticals Holding AG worth?
The market values Santhera Pharmaceuticals Holding AG at about CHF 239M (market capitalisation, as of Nov 10, 2026). Per share that is CHF 14.94; our models calculate a fair value of CHF 15.04 per share.
What do the bullish and bearish scenarios say about SANN?
Our models span a range for Santhera Pharmaceuticals Holding AG: cautious scenario CHF 11.28, base CHF 15.04, optimistic CHF 18.80 per share (as of Nov 10, 2026, price CHF 14.94). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Santhera Pharmaceuticals Holding AG (SANN)?
Balance-sheet figures for Santhera Pharmaceuticals Holding AG (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is SANN from its 52-week high?
Santhera Pharmaceuticals Holding AG trades at CHF 14.94, about 19% below its 52-week high of CHF 18.54 and 45% above the low of CHF 10.28 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 15.04 is for.
Which stocks are comparable to Santhera Pharmaceuticals Holding AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Santhera Pharmaceuticals Holding AG stock attractive at the current price?
The data as of Nov 10, 2026: price CHF 14.94, calculated fair value CHF 15.04 (+1%), Quality Score 19/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Santhera Pharmaceuticals Holding AG currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Santhera Pharmaceuticals Holding AG (SANN)?
The closing price on Nov 10, 2026 was CHF 14.94. Our estimate is CHF 15.04, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Santhera Pharmaceuticals Holding AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Santhera Pharmaceuticals Holding AG

How large is the market capitalisation of Santhera Pharmaceuticals Holding AG (SANN)?
The market capitalisation of Santhera Pharmaceuticals Holding AG is CHF 239M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Santhera Pharmaceuticals Holding AG (SANN)?
The price-to-sales ratio of Santhera Pharmaceuticals Holding AG is 2.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Santhera Pharmaceuticals Holding AG (SANN)?
Earnings per share at Santhera Pharmaceuticals Holding AG are CHF −2.24. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Santhera Pharmaceuticals Holding AG (SANN)?
The net margin of Santhera Pharmaceuticals Holding AG is −31.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Santhera Pharmaceuticals Holding AG (SANN)?
The return on equity (ROE) of Santhera Pharmaceuticals Holding AG is −620% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Santhera Pharmaceuticals Holding AG (SANN)?
On an EBIT basis the return on assets of Santhera Pharmaceuticals Holding AG is −25.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Santhera Pharmaceuticals Holding AG (SANN)?
The operating margin of Santhera Pharmaceuticals Holding AG is −13.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Santhera Pharmaceuticals Holding AG (SANN)?
Revenue at Santhera Pharmaceuticals Holding AG is growing +101% versus a year earlier (3y avg +118%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Santhera Pharmaceuticals Holding AG (SANN) generate?
The free cash flow of Santhera Pharmaceuticals Holding AG is −CHF 34.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Santhera Pharmaceuticals Holding AG (SANN) carry?
The net debt of Santhera Pharmaceuticals Holding AG is CHF 75.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Santhera Pharmaceuticals Holding AG in the live analysis

One click puts Santhera Pharmaceuticals Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.